ID   2B8 [Mouse hybridoma against human MS4A1]
AC   CVCL_KR60
SY   IDEC-2B8
DR   Wikidata; Q54584310
RX   Patent=US5736137;
RX   PubMed=7506951;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11388.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized rituximab (IDEC-C2B8) therapeutic antibody.
CC   Monoclonal antibody isotype: IgG1, kappa.
CC   Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_6450 ! Sp2/01-Ag
CA   Hybridoma
DT   Created: 22-08-17; Last updated: 21-03-23; Version: 6
//
RX   Patent=US5736137;
RA   Anderson D.R., Hanna N., Leonard J.E., Newman R.A., Reff M.E.,
RA   Rastetter W.H.;
RT   "Therapeutic application of chimeric and radiolabeled antibodies to
RT   human B lymphocyte restricted differentiation antigen for treatment of
RT   B cell lymphoma.";
RL   Patent number US5736137, 07-Apr-1998.
//
RX   PubMed=7506951; DOI=10.1182/blood.V83.2.435.435;
RA   Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E.,
RA   Raab R., Newman R.A., Hanna N., Anderson D.R.;
RT   "Depletion of B cells in vivo by a chimeric mouse human monoclonal
RT   antibody to CD20.";
RL   Blood 83:435-445(1994).
//